VolitionRX Ltd VNRX

ASE: VNRX | ISIN: US9286611077   15/11/2024
0,680 USD (-5,56%)
(-5,56%)   15/11/2024

31 mei 2022 · Volition Achieves CE Mark for Nu.Q® NETs Test · Persbericht

11 mei 2022 · VolitionRx Limited Announces First Quarter 2022 Financial Results and Business Update · Persbericht

6 mei 2022 · VolitionRx Limited Schedules First Quarter 2022 Earnings Conference Call and Business Update · Persbericht

5 mei 2022 · VolitionRx Limited to Host Capital Markets Day on Friday May 13 · Persbericht

25 april 2022 · Volition Launches its Nu.Q® Vet Cancer Test in Asia Through its Appointed Distributor SAGE Healthcare · Persbericht

6 april 2022 · Volition appoints Sharon Ballesteros as U.S. Head of Quality and Development Process · Persbericht

30 maart 2022 · VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update · Persbericht

29 maart 2022 · Volition Signs Exclusive $28 million License and Supply Agreement with Heska Corporation to Distribute Nu.Q® Vet Cancer Screening Test at the Point of Care · Persbericht

29 maart 2022 · Heska Corporation Signs Exclusive Agreement to Introduce Nu.Q® Vet Cancer Screening Test, First-Ever Point of Care Cancer Screen · Persbericht

28 maart 2022 · VolitionRx Limited Schedules Full Fiscal Year 2021 Earnings Conference Call and Business Update · Persbericht

20 januari 2022 · Volition presents study data at ASCO GI 2022 on circulating nucleosomes for the detection of colorectal cancer and high-risk advanced adenomas · Persbericht

16 december 2021 · Volition Executes its First Supply and Licensing Contract for its Nu.Q® Vet Cancer Screening Test in Asia · Persbericht

9 december 2021 · Life Sciences Virtual Investor Conference: Company Executives Present Live December 16th · Persbericht

10 november 2021 · VolitionRx Limited Announces Third Quarter 2021 Financial Results and Business Update · Persbericht

8 november 2021 · VolitionRx Limited Schedules Third Quarter 2021 Earnings Conference Call and Business Update · Persbericht

4 november 2021 · Volition Veterinary Presents Two Posters at the 2021 Veterinary Cancer Society Conference · Persbericht

11 augustus 2021 · VolitionRx Limited Announces Second Quarter 2021 Financial Results and Business Update · Persbericht

4 augustus 2021 · VolitionRx Limited Schedules Second Quarter 2021 Earnings Conference Call and Business Update · Persbericht

22 juli 2021 · Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring · Persbericht

11 mei 2021 · VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update · Persbericht

Mijn selecties